NitroMed creates VP-sales
Executive Summary
NitroMed names Bristol-Myers Squibb VP-Private Sector Strategy & Accounts Gerald Bruce to the new position of VP-sales. Bruce's focus will initially be on the uptake of BiDil, the company's first marketed product, which launched in July 2005. At Bristol, Bruce worked in the managed care arena with responsibilities in formulary placement and sales. He also led multi-regional cardiovascular and metabolic sales at Bristol and worked as a product director for Johnson & Johnson...
You may also be interested in...
NitroMed Aims To Revive BiDil With CEO Change, Managed Care Push
NitroMed's strategy for jump-starting sales of BiDil includes renewed efforts to get favorable formulary placement for the heart failure drug
Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings
Japan now allows pseudonymized personal data for medical use under a licensing system for wider use of real-world data. Meanwhile, a national cost-effectiveness assessment scheme has slashed reimbursement prices for Lagevrio and Kerendia, and Alexion’s Voydeya has been added to the reimbursement tariff.
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.